Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is a China‑based, research‑driven pharmaceutical company headquartered in Lianyungang, Jiangsu, and listed on the Shanghai Stock Exchange. It develops and manufactures innovative medicines and high‑quality generics spanning oncology, anesthesia and pain management, cardiovascular and metabolic diseases, anti‑infectives, and diagnostic imaging.
Hengrui integrates discovery chemistry, process development, and scale manufacturing across small‑molecule drugs, biologics, active pharmaceutical ingredients (APIs), and finished dosage forms. The company is a significant domestic producer of non‑ionic iodinated contrast media and related intermediates, linking its activities closely to the chemical value chain. Its operations include multiple R&D and manufacturing sites in China, with products supplied to the domestic market and exported to international markets.
Beyond commercialized products, Hengrui advances a pipeline that includes targeted therapies and immuno‑oncology agents, and it engages in collaborations and out‑licensing for select assets. The company’s role in the chemical industry centers on the large‑scale synthesis of APIs, intermediates, and specialty radiographic agents, supported by process optimization and quality systems for regulated markets.
Also known as Hengrui Medicine.
Phase‑1 ready oral GLP‑1/GIP dual agonist with up to $2.6bn deal value including $300m upfront; development and commercial rights exclude Greater China.
Strong oncology and animal health sales, positive trial results, and strategic acquisitions drive growth. 2026 outlook projects sales up to $67B, with EPS impacted by acquisition charges.
